Janet L. Smart

Harbour Biomed Shanghai Co. Ltd. engages in the development of therapeutics for cancer, especially in immuno-oncology. The company is headquartered in Shanghai, China.

EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016.

Shangbay Capital Management Co. LLC (Shangbay Capital) is a venture capital firm founded in 2015. The firm is headquartered in Palo Alto, California.

Part of AbbVie, Inc., AbbVie Bioresearch Center, Inc. is a company that provides drug discovery, development sciences, and biologics research services. The company is based in Worcester, MA.

Harbour Antibodies BV engages in the production of antibodies and VH domains for therapy. The firm develops two types of human immunoglobulin gene transgenic mice such as mice that generate conventional tetrameric antibodies comprising two heavy and two light immunoglobulin chains (H2L2); and alternatively, mice that generate heavy chain only antibodies comprising two immunoglobulin heavy chains with no light chains (HCAbs). The company was founded by Frank Grosveld in 2006 and is headquartered in Rotterdam, the Netherlands.

Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA.